HAVCR2 and gastric cancer: Significant differences were observed for the Tim-3+ PD-1+ CD4+/CD8+ percentage in stage III patients compared to stage I/II GC patients (17.2% vs. 9.02%, p = 0.0112, Fig. 5a for CD4+; 28.4% vs. 7.47%, p = 0.0013, Fig. 5b for CD8+).